Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Neumora Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2023
FY2024
FY2025
Research and development
91.7
143
201
176
General and administrative
31.1
45.5
62.5
60.1
Operating expenses
136
252
263
241
Operating income
-136
-252
-263
-241
Interest expense
0
2.01
Interest income
19.9
8.34
Other non-operating income
4.97
16.4
19.9
4.36
Pre-tax income
-131
-236
-244
-237
Income tax
0.27
0.18
0.13
Net income
-131
-236
-244
-237
EBITDA
-135
-251
-263
-241
EPS, basic
-4.81
-3.63
-1.53
-1.45
EPS, diluted
-4.81
-3.63
-1.53
-1.45
Shares, basic (weighted)
27.2
65
159
163
Shares, diluted (weighted)
27.2
65
159
163
Balance sheet
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
241
374
142
183
Short-term investments
131
79.9
165
Other current assets
16
24.3
5.26
8.01
Total current assets
388
478
314
191
Property, plant and equipment
2.41
1.79
1.14
0.04
Lease right-of-use assets
8.23
5.07
1.78
0.42
Long-term investments
23.5
9.85
Other non-current assets
2.91
0
0.05
Total assets
426
496
317
191
Accounts payable
7.15
0.34
3.31
3.38
Accrued liabilities
11.5
21.3
24.6
28.8
Short-term debt
60
Total current liabilities
23.7
25.1
29.9
32.5
Long-term debt
0
54.5
Lease liabilities
5.07
1.85
0
0.19
Total liabilities
29.4
27.1
29.9
87.2
Total debt
0
54.5
Paid-in capital
21.4
1,173
1,234
1,288
Retained earnings
-468
-703
-947
-1,184
Other comprehensive income
-0.77
-0.08
0.06
Shareholders' equity
-447
469
287
104
Total equity
-447
469
287
104
Total liabilities and equity
426
496
317
191
Shares outstanding
32.6
159
162
174
Cash flow statement
FY2023
FY2023
FY2024
FY2025
Net income
-131
-236
-244
-237
Depreciation and amortization
0.59
0.67
0.63
0.21
Stock-based compensation
8.3
17.2
40
29.9
Change in payables
-1.25
-0.58
2.87
0.07
Cash from operations
-115
-163
-183
-206
Capital expenditures
-0.51
-0.12
Purchases of investments
-226
-109
-312
-82.9
Sales and maturities of investments
71.9
178
Cash from investing
-168
64.4
-70.6
169
Stock issued
2.66
0.81
7.48
0
Cash from financing
116
232
21.6
77.1
Net change in cash
-167
133
-232
39.2
Free cash flow
-115
-163
Interest paid
3.22
Income taxes paid
0.47
0.32
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.68 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-477.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-169.9%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-63.8%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-39.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-23.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
2.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
81.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.50x
Current assets / current liabilities.
Quick ratio
4.21x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.21x
(Cash + short-term investments) / current liabilities.
Debt / equity
1.19x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
42.2%
Total debt / total assets.
Liabilities / assets
64.5%
Total liabilities / total assets.
Net debt
-$63.9M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.97
Cash from operations / diluted weighted shares.
Book value per share
$0.24
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
2.86x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.86x
Market cap / tangible book value, when positive.
Earnings yield
-167.1%
Net income / market cap (the inverse of P/E).
Was Neumora Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $236.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.